With 44.74 million shares changed hands, the volume of the stock remained heavier than its average volume of 18.42 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1275 whereas the lowest price it dropped to was $0.1011. The 52-week range on EYEN shows that it touched its highest point at $2.57 and its lowest point at $0.08 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 1.32.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EYEN was up-trending over the past week, with a rise of 27.60%, but this was up by 22.90% over a month. Three-month performance dropped to -75.10% while six-month performance fell -86.31%. The stock lost -93.54% in the past year, while it has lost -17.67% so far this year. A look at the trailing 12-month EPS for EYEN yields -0.73 with Next year EPS estimates of -0.46. For the next quarter, that number is -0.10. This implies an EPS growth rate of 6.06% for this year and 25.81% for next year.
Float and Shares Shorts:
At present, 111.42 million EYEN shares are outstanding with a float of 109.29 million shares on hand for trading. On 2024-10-31, short shares totaled 2.14 million, which was 248.99999999999997 higher than short shares on 1727654400. In addition to Mr. Michael M. Rowe as the firm’s CEO, President & Director, Dr. Tsontcho Ianchulev M.D., M.P.H., MPH serves as its Co-Founder & Executive Director.
Institutional Ownership:
Through their ownership of 0.13726 of EYEN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, EYEN reported revenue of $1625.0 and operating income of -$7331927.0. The EBITDA in the recently reported quarter was -$6998263.0 and diluted EPS was -$0.11.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With EYEN analysts setting a high price target of 2.0 and a low target of 2.0, the average target price over the next 12 months is 2.0. Based on these targets, EYEN could surge 1566.67% to reach the target high and rise by 1566.67% to reach the target low. Reaching the average price target will result in a growth of 1566.67% from current levels.
Analysts have provided yearly estimates in a range of -$0.5828 being high and -$0.6448 being low. For EYEN, this leads to a yearly average estimate of -$0.62.
